X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the divestment, Esteve expand its rare disease business portfolio, by including Metopirone (metyrapone), can be used to treat the signs and symptoms of Cushing's syndrome by lowering high levels of cortisol a hormone produced by the adrenal glands.
Lead Product(s): Metyrapone
Therapeutic Area: Endocrinology Product Name: Metopirone
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Esteve Healthcare
Deal Size: $294.2 million Upfront Cash: $203.3 million
Deal Type: Divestment April 25, 2024
Details:
HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).
Lead Product(s): Ulipristal Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ellaOne
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Perrigo Company plc
Deal Size: Undisclosed Upfront Cash: $2,100.0 million
Deal Type: Acquisition September 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
